We are advancing the clinical development of a pipeline of investigational therapies for patients with a range of hematological malignancies and solid tumors. When patients participate in our clinical trials and take one of our drug candidates, we recognize the time and effort it takes for patients and their families to commit to the study. So, it’s important to validate that trust by considering how each study can best contribute to the greater good of all patients. This includes not only evaluating the safety and efficacy of each drug candidate, but considering factors related to patient convenience, adoption and compliance so that patients are provided the opportunity to get the most benefit from each prospective therapy.
About Clinical Trials
Clinical trials are research studies designed to evaluate the potential of drug candidates and are a critical part of the process for bringing new safe and effective medicines to patients. All drug candidates are required to go through a series of clinical trials in order to seek approval as medicines by regulatory agencies like the U.S. Food and Drug Administration, or FDA. Some basic information on clinical trials can be found on the FDA website.
Clinical trials may be an appropriate option for some patients where standard or approved therapies have not been successful in treating or managing a disease or condition. In addition to the potential to provide an investigational treatment, clinical trials also offer the opportunity to provide an important contribution to the knowledge around new technologies and the understanding of disease.
MEI is actively recruiting patients to participate in clinical trials to evaluate our investigational cancer therapies.